WuXi AppTec's Corporate Venture Fund and GV participated in a round that came two years after the drug discovery system developer raised money at a unicorn valuation.
US-based drug discovery technology developer Insitro received $143m in series B funding from investors including subsidiaries of internet and technology group Alphabet and pharmaceutical firm WuXi AppTec yesterday.
WuXi AppTec took part in the round through its Corporate Venture Fund while Alphabet invested through GV, and life sciences real estate investment trust Alexandria Real Estate Equities took part through its Alexandria Venture Investments unit.
Venture capital firm Andreessen Horowitz led the round, which included Canada Pension Plan Investment Board, Casdin…
